Apr 072020
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– UK, Glasgow – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins, today announced the closing of a USD $7.5m Series A funding round led by Advent Life Sciences. Seed round funders the Scottish ...

Amphista Therapeutics appoints Satish Jindal as Board Chairman and raises $7.5m Series A funding led by Advent Life Sciences

Amphista Therapeutics appoints Satish Jindal as Board Chairman and raises $7.5m Series A funding led by Advent Life Sciences

From:: Amphista Therapeutics appoints Satish Jindal as Board Chairman and raises $7.5m Series A funding led by Advent Life Sciences

Sorry, the comment form is closed at this time.